<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pediatr</journal-id><journal-id journal-id-type="iso-abbrev">Front Pediatr</journal-id><journal-id journal-id-type="publisher-id">Front. Pediatr.</journal-id><journal-title-group><journal-title>Frontiers in Pediatrics</journal-title></journal-title-group><issn pub-type="epub">2296-2360</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098452</article-id><article-id pub-id-type="doi">10.3389/fped.2025.1589770</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pediatrics</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Prognosis of different types of acute infection in the first episode of childhood acute leukemia</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Li</surname><given-names>Shasha</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref><xref rid="an1" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2998270/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Shanshan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="an1" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yi</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Jia</surname><given-names>Shuyuan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Luan</surname><given-names>Kexin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Feng</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/></contrib></contrib-group><aff id="aff1"><label><sup>1</sup></label><institution>Department of Oncology, The Second Affiliated Hospital of Harbin Medical University</institution>, <addr-line>Harbin</addr-line>, <country>China</country></aff><aff id="aff2"><label><sup>2</sup></label><institution>Department of Surgery, The Second Affiliated Hospital of Harbin Medical University</institution>, <addr-line>Harbin</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p><bold>Edited by:</bold> Zhongjie Shi, Wayne State University, United States</p></fn><fn fn-type="edited-by"><p><bold>Reviewed by:</bold> Ying Meng, Chongqing Medical University, China</p><p>Yuebo Yang, Third Affiliated Hospital of Sun Yat-sen University, China</p></fn><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Shasha Li <email>lishasha2727@163.com</email></corresp><fn fn-type="equal" id="an1"><label>
<sup>&#x02020;</sup>
</label><p>These authors share first authorship</p></fn></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>13</volume><elocation-id>1589770</elocation-id><history><date date-type="received"><day>07</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>10</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Li, Li, Chen, Jia, Luan and Cui.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Li, Li, Chen, Jia, Luan and Cui</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Objective</title><p>The aim of the present study was to determine the prognosis of different types of acute infection in pediatric leukemia patients.</p></sec><sec><title>Methods</title><p>A retrospective study was carried out on pediatric leukemia patients with acute infections admitted to the Second Affiliated Hospital of Harbin Medical University between 1 September 2004 and 31 August 2022. Clinical characteristics, diagnostic findings, and prognostic outcomes were extracted from the eligible cases and analyzed.</p></sec><sec><title>Results</title><p>There were 36 cases of acute myeloid leukemia (AML) and 72 cases of acute lymphoblastic leukemia (ALL) that met the inclusion criteria. There were significant differences in the incidence of pneumonia (47.2% vs. 27.8%, <italic>p</italic>&#x02009;=&#x02009;0.045) and sepsis (19.4% vs. 2.8%, <italic>p</italic>&#x02009;=&#x02009;0.006) between the AML and ALL groups. There were 10 cases with a poor prognosis and 26 cases with a favorable prognosis in the AML group. There were no significant differences between the poor prognosis and the favorable prognosis groups except for age (14.2&#x02009;&#x000b1;&#x02009;1.2&#x02005;years vs. 9.6&#x02009;&#x000b1;&#x02009;4.3&#x02005;years, <italic>p</italic>&#x02009;=&#x02009;0.003). There were 14 cases with a poor prognosis and 58 cases with a favorable prognosis in the ALL group. There were no significant differences between the poor prognosis and favorable prognosis groups except for age (13.4&#x02009;&#x000b1;&#x02009;2.7&#x02005;years vs. 9.2&#x02009;&#x000b1;&#x02009;4.7&#x02005;years, <italic>p</italic>&#x02009;=&#x02009;0.002).</p></sec><sec><title>Conclusions</title><p>There were significantly more incidence of pneumonia and sepsis in children with AML. Younger AML and ALL children with acute infections have more favorable prognoses than older children.</p></sec></abstract><kwd-group><kwd>prognosis</kwd><kwd>acute infection</kwd><kwd>acute pediatric leukemia</kwd><kwd>acute lymphoblastic leukemia</kwd><kwd>acute myeloid leukemia</kwd><kwd>children</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research and/or publication of this article.</funding-statement></funding-group><counts><fig-count count="0"/><table-count count="4"/><equation-count count="0"/><ref-count count="26"/><page-count count="5"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Pediatric Infectious Diseases</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Acute pediatric leukemia is a serious condition in childhood. In 2020, there were 67,008 new reported cases of pediatric leukemia globally, with male patients accounting for 57.85% of all cases (<xref rid="B1" ref-type="bibr">1</xref>). The survival rates of pediatric acute lymphoblastic leukemia (ALL) have been reported to be in the range of 83%&#x02013;94% (<xref rid="B2" ref-type="bibr">2</xref>), compared to 65%&#x02013;70% for pediatric acute myeloid leukemia (AML) (<xref rid="B3" ref-type="bibr">3</xref>). Infections may increase morbidity and mortality in patients with acute pediatric leukemia who have a much higher risk of infection, potentially due to their malfunctioning immune system, as well as the burden of their therapies, which could lead to repeated, prolonged, and complicated deterioration of immune cells (<xref rid="B4" ref-type="bibr">4</xref>). Infections in acute pediatric leukemia patients, besides causing a higher mortality, also lead to prolonged hospitalizations, disrupt chemotherapy schedules, negatively affect patients&#x02019; quality of life, and escalate the demand for extra healthcare resources and costs (<xref rid="B5" ref-type="bibr">5</xref>). This multifaceted impact underscores the need for vigilant infection management to optimize treatment outcomes and patient wellbeing.</p><p>In this study, we analyzed the prognosis of different types of acute infection in patients with pediatric leukemia and showed the most relevant factors that could affect the prognosis.</p></sec><sec sec-type="methods" id="s2"><label>2</label><title>Methods</title><p>This retrospective study was conducted in pediatric leukemia patients with acute infections admitted to the Second Affiliated Hospital of Harbin Medical University between 1 September 2004 and 31 August 2022. The inclusion criteria were as follows: (1) patients aged under 18&#x02005;years; (2) patients diagnosed with acute leukemia according to the established criteria (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>); (3) patients experiencing a first episode of leukemia with no prior treatment; (4) patients diagnosed with acute infection based on clinical symptoms and signs, supported by laboratory test results (<xref rid="B8" ref-type="bibr">8</xref>); (5) patients with signed informed consent to participate in medical research upon admission. The exclusion criteria were as follows: (1) patients with chronic infectious diseases; (2) patients with other types of cancer; (3) patients with COVID-19 infection, confirmed by nucleic acid amplification tests (NAATs) of nasal swab samples (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>); (4) patients with acute conditions needing surgical treatments; and (5) incomplete data.</p><p>Clinical characteristics such as age, gender, hospital stay, and different types of acute infections, including upper respiratory tract infection, pneumonia, pleurisy, sepsis, bronchitis, urinary tract infection, oral infection, perianal infection, acute enteritis, herpetic angina, skin infection, and soft tissue infection, were abstracted and analyzed.</p><p>Poor prognoses referred to uncontrolled infection or death before discharge from hospital. Favorable prognoses referred to controlled infection or cure of infection before discharge from the hospital.</p><sec id="s2a"><label>2.1</label><title>Statistical analysis</title><p>Clinical data were extracted and summarized in an Excel file, then analyzed using SPSS 25.0. The <italic>t</italic>-test was used for continuous data and the chi-square test was used for categorical data. Fisher&#x02019;s exact test was used when the number in the group was less than five.</p><p>The level of significance was set at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 (two sided).</p></sec></sec><sec sec-type="results" id="s3"><label>3</label><title>Results</title><p>There were 36 cases of AML and 72 cases of ALL that met the inclusion criteria. There were no differences between the AML and ALL groups in terms of patient age, gender, hospital stay, upper respiratory tract infection, pleurisy, bronchitis, urinary tract infection, oral infection, perianal infection, acute enteritis, herpetic angina, skin infection, soft tissue infection, or poor prognosis (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05 for all comparisons). There were significant differences in the incidence of pneumonia (47.2% vs. 27.8%, <italic>p</italic>&#x02009;=&#x02009;0.045) and sepsis (19.4% vs. 2.8%, <italic>p</italic>&#x02009;=&#x02009;0.006) between the AML and ALL groups (<xref rid="T1" ref-type="table">Table&#x000a0;1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinical characteristics of patients in the AML and ALL groups.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Items</th><th valign="top" align="center" rowspan="1" colspan="1">AML&#x02009;+&#x02009;ALL (<italic>n</italic>&#x02009;=&#x02009;108)</th><th valign="top" align="center" rowspan="1" colspan="1">AML (<italic>n</italic>&#x02009;=&#x02009;36)</th><th valign="top" align="center" rowspan="1" colspan="1">ALL (<italic>n</italic>&#x02009;=&#x02009;72)</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="center" rowspan="1" colspan="1">10.3&#x02009;&#x000b1;&#x02009;4.6</td><td valign="top" align="center" rowspan="1" colspan="1">10.9&#x02009;&#x000b1;&#x02009;4.2<xref rid="table-fn2" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">10.0&#x02009;&#x000b1;&#x02009;4.7<xref rid="table-fn2" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">0.337<xref rid="table-fn3" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">74 (68.5%)</td><td valign="top" align="center" rowspan="1" colspan="1">24 (66.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">50 (69.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.770<xref rid="table-fn4" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hospital stay (days)</td><td valign="top" align="center" rowspan="1" colspan="1">25.1&#x02009;&#x000b1;&#x02009;16.2</td><td valign="top" align="center" rowspan="1" colspan="1">28.6&#x02009;&#x000b1;&#x02009;15.1<xref rid="table-fn2" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">23.3&#x02009;&#x000b1;&#x02009;16.4<xref rid="table-fn2" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">0.109<xref rid="table-fn3" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Upper respiratory tract infection</td><td valign="top" align="center" rowspan="1" colspan="1">50 (46.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (33.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">38 (52.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.056<xref rid="table-fn4" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pneumonia</td><td valign="top" align="center" rowspan="1" colspan="1">37 (34.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">17 (47.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">20 (27.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.045</bold>
<xref rid="table-fn6" ref-type="table-fn">*</xref>
<xref rid="table-fn4" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pleurisy</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (1.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">1<xref rid="table-fn5" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sepsis</td><td valign="top" align="center" rowspan="1" colspan="1">9 (8.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (19.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (2.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.006</bold>
<xref rid="table-fn6" ref-type="table-fn">*</xref>
<xref rid="table-fn5" ref-type="table-fn">
<sup>d</sup>
</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bronchitis</td><td valign="top" align="center" rowspan="1" colspan="1">5 (4.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (5.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (4.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">1<xref rid="table-fn5" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Urinary tract infection</td><td valign="top" align="center" rowspan="1" colspan="1">2 (1.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (1.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">1<xref rid="table-fn5" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Oral infection</td><td valign="top" align="center" rowspan="1" colspan="1">8 (7.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (11.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (5.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.437<xref rid="table-fn5" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Perianal infection</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">0.333<xref rid="table-fn5" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Acute enteritis</td><td valign="top" align="center" rowspan="1" colspan="1">4 (3.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (4.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">1<xref rid="table-fn5" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Herpetic angina</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (1.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">1<xref rid="table-fn5" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Skin infection</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (1.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">1<xref rid="table-fn5" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Soft tissue infection</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">0.333<xref rid="table-fn5" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Poor prognosis</td><td valign="top" align="center" rowspan="1" colspan="1">24 (22.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (27.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (19.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.326<xref rid="table-fn4" ref-type="table-fn"><sup>c</sup></xref></td></tr></tbody></table><table-wrap-foot><fn id="table-fn1"><p>Poor prognosis referred to uncontrolled infection or death. AML, acute myeloid leukemia; ALL, acute lymphocytic leukemia.</p></fn><fn id="table-fn2a"><p>Bold values represented <italic>p</italic> &#x0003c; 0.05.</p></fn><fn id="table-fn2"><label>
<sup>a</sup>
</label><p>Mean&#x02009;&#x000b1;&#x02009;standard deviation.</p></fn><fn id="table-fn3"><label>
<sup>b</sup>
</label><p><italic>t</italic>-test.</p></fn><fn id="table-fn4"><label>
<sup>c</sup>
</label><p>Chi-square test.</p></fn><fn id="table-fn5"><label>
<sup>d</sup>
</label><p>Fisher&#x02019;s exact test.</p></fn><fn id="table-fn6"><label>*</label><p><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 between AML and ALL.</p></fn></table-wrap-foot></table-wrap><p>Patients in the AML or ALL groups were further analyzed based on their prognosis at discharge. There were 10 cases with a poor prognosis and 26 cases with a favorable prognosis in the AML group. There were no significant differences between the poor prognosis and favorable prognosis groups except for age (14.2&#x02009;&#x000b1;&#x02009;1.2&#x02005;years vs. 9.6&#x02009;&#x000b1;&#x02009;4.3&#x02005;years, <italic>p</italic>&#x02009;=&#x02009;0.003) (<xref rid="T2" ref-type="table">Table&#x000a0;2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Clinical characteristics of patients in the AML group.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Items</th><th valign="top" align="center" rowspan="1" colspan="1">Poor prognosis (<italic>n</italic>&#x02009;=&#x02009;10)</th><th valign="top" align="center" rowspan="1" colspan="1">Favorable prognosis (<italic>n</italic>&#x02009;=&#x02009;26)</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="center" rowspan="1" colspan="1">14.2&#x02009;&#x000b1;&#x02009;1.2<xref rid="table-fn8" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">9.6&#x02009;&#x000b1;&#x02009;4.3<xref rid="table-fn8" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.003</bold>
<xref rid="table-fn9" ref-type="table-fn">
<sup>b</sup>
</xref>
<xref rid="table-fn12" ref-type="table-fn">*</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="center" rowspan="1" colspan="1">5 (50%)</td><td valign="top" align="center" rowspan="1" colspan="1">19 (73.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.987<xref rid="table-fn10" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hospital stay (days)</td><td valign="top" align="center" rowspan="1" colspan="1">33.2&#x02009;&#x000b1;&#x02009;12.3<xref rid="table-fn8" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">26.8&#x02009;&#x000b1;&#x02009;15.7<xref rid="table-fn8" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">0.270<xref rid="table-fn9" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Upper respiratory tract infection</td><td valign="top" align="center" rowspan="1" colspan="1">4 (40%)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (30.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.700<xref rid="table-fn11" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pneumonia</td><td valign="top" align="center" rowspan="1" colspan="1">7 (70%)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (42.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.137<xref rid="table-fn10" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sepsis</td><td valign="top" align="center" rowspan="1" colspan="1">4 (40%)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (11.5%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.076<xref rid="table-fn12" ref-type="table-fn">*</xref><xref rid="table-fn11" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bronchitis</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (7.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">1<xref rid="table-fn11" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Urinary tract infection</td><td valign="top" align="center" rowspan="1" colspan="1">1 (10%)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">0.278<xref rid="table-fn11" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Oral infection</td><td valign="top" align="center" rowspan="1" colspan="1">2 (20%)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (7.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.305<xref rid="table-fn11" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Perianal infection</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (3.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">1<xref rid="table-fn11" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Acute enteritis</td><td valign="top" align="center" rowspan="1" colspan="1">1 (10%)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">0.278<xref rid="table-fn11" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Soft tissue infection</td><td valign="top" align="center" rowspan="1" colspan="1">1 (10%)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">0.278<xref rid="table-fn11" ref-type="table-fn"><sup>d</sup></xref></td></tr></tbody></table><table-wrap-foot><fn id="table-fn7"><p>Poor prognosis referred to uncontrolled infection or death before discharged from hospital. Favorable prognosis referred to controlled infection or cure before discharged from hospital. AML, acute myeloid leukemia.</p></fn><fn id="table-fn7a"><p>Bold values represented <italic>p</italic> &#x0003c; 0.05.</p></fn><fn id="table-fn8"><label>
<sup>a</sup>
</label><p>Mean&#x02009;&#x000b1;&#x02009;standard deviation.</p></fn><fn id="table-fn9"><label>
<sup>b</sup>
</label><p><italic>t</italic>-test.</p></fn><fn id="table-fn10"><label>
<sup>c</sup>
</label><p>Chi-square test.</p></fn><fn id="table-fn11"><label>
<sup>d</sup>
</label><p>Fisher&#x02019;s exact test.</p></fn><fn id="table-fn12"><label>*</label><p><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></fn></table-wrap-foot></table-wrap><p>In the same token, there were 14 cases with a poor prognosis and 58 cases with a favorable prognosis in the ALL group. There were no significant differences between the poor prognosis and favorable prognosis groups except for age (13.4&#x02009;&#x000b1;&#x02009;2.7&#x02005;years vs. 9.2&#x02009;&#x000b1;&#x02009;4.7&#x02005;years, <italic>p</italic>&#x02009;=&#x02009;0.002) (<xref rid="T3" ref-type="table">Table&#x000a0;3</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Clinical characteristics of patients in the ALL group.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Items</th><th valign="top" align="center" rowspan="1" colspan="1">Poor prognosis (<italic>n</italic>&#x02009;=&#x02009;14)</th><th valign="top" align="center" rowspan="1" colspan="1">Favorable prognosis (<italic>n</italic>&#x02009;=&#x02009;58)</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="center" rowspan="1" colspan="1">13.4&#x02009;&#x000b1;&#x02009;2.7<xref rid="table-fn14" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">9.2&#x02009;&#x000b1;&#x02009;4.7<xref rid="table-fn14" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.002</bold>
<xref rid="table-fn15" ref-type="table-fn">
<sup>b</sup>
</xref>
<xref rid="table-fn18" ref-type="table-fn">*</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="center" rowspan="1" colspan="1">9 (64.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">41 (70.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.641<xref rid="table-fn16" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hospital stay (days)</td><td valign="top" align="center" rowspan="1" colspan="1">26.8&#x02009;&#x000b1;&#x02009;14.9<xref rid="table-fn14" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">22.4&#x02009;&#x000b1;&#x02009;16.6<xref rid="table-fn14" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">0.380<xref rid="table-fn15" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Upper respiratory tract infection</td><td valign="top" align="center" rowspan="1" colspan="1">6 (42.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">32 (55.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.407<xref rid="table-fn16" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pneumonia</td><td valign="top" align="center" rowspan="1" colspan="1">3 (21.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">17 (29.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.744<xref rid="table-fn17" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pleurisy</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (1.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">1<xref rid="table-fn17" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sepsis</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (3.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">1<xref rid="table-fn17" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bronchitis</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (5.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">1<xref rid="table-fn17" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Urinary tract infection</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (1.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">
<sup>1</sup>
<xref rid="table-fn17" ref-type="table-fn">
<sup>d</sup>
</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Oral infection</td><td valign="top" align="center" rowspan="1" colspan="1">1 (7.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (5.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">1<xref rid="table-fn17" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Acute enteritis</td><td valign="top" align="center" rowspan="1" colspan="1">1 (7.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (3.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.483<xref rid="table-fn17" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Herpetic angina</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (1.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">1<xref rid="table-fn17" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Skin infection</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (1.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">1<xref rid="table-fn17" ref-type="table-fn"><sup>d</sup></xref></td></tr></tbody></table><table-wrap-foot><fn id="table-fn13"><p>ALL, acute lymphocytic leukemia.</p></fn><fn id="table-fn13a"><p>Bold values represented <italic>p</italic> &#x0003c; 0.05.</p></fn><fn id="table-fn14"><label>
<sup>a</sup>
</label><p>Mean&#x02009;&#x000b1;&#x02009;standard deviation.</p></fn><fn id="table-fn15"><label>
<sup>b</sup>
</label><p><italic>t</italic>-test.</p></fn><fn id="table-fn16"><label>
<sup>c</sup>
</label><p>Chi-square test.</p></fn><fn id="table-fn17"><label>
<sup>d</sup>
</label><p>Fisher&#x02019;s exact test.</p></fn><fn id="table-fn18"><label>*</label><p><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></fn></table-wrap-foot></table-wrap><p>The age distribution of prognosis is shown in <xref rid="T4" ref-type="table">Table&#x000a0;4</xref>. A decreasing trend in favorable prognosis was observed with increasing age in participants in both the ALL and AML groups. There was a significant difference in prognosis between participants aged &#x0003c;12&#x02005;years and those aged &#x02265;12&#x02005;years in both cohorts (ALL: <italic>p</italic>&#x02009;=&#x02009;0.0021; AML: <italic>p</italic>&#x02009;=&#x02009;0.0004).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Age distribution of prognosis.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="2" colspan="1">Age (years)</th><th valign="top" align="center" colspan="4" rowspan="1">ALL</th><th valign="top" align="center" colspan="4" rowspan="1">AML</th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">Good (<italic>n</italic>)</th><th valign="top" align="center" rowspan="1" colspan="1">Poor (<italic>n</italic>)</th><th valign="top" align="center" rowspan="1" colspan="1">Total (<italic>n</italic>)</th><th valign="top" align="center" rowspan="1" colspan="1">Good (%)</th><th valign="top" align="center" rowspan="1" colspan="1">Good (<italic>n</italic>)</th><th valign="top" align="center" rowspan="1" colspan="1">Poor (<italic>n</italic>)</th><th valign="top" align="center" rowspan="1" colspan="1">Total (<italic>n</italic>)</th><th valign="top" align="center" rowspan="1" colspan="1">Good (%)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">100</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">100</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">100</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">100</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">100</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">66.7</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">50</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">100</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">100</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">100</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">100</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">5</td><td valign="top" align="center" rowspan="1" colspan="1">60</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">66.7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="center" rowspan="1" colspan="1">5</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">83.3</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">50</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">50</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">50</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="center" rowspan="1" colspan="1">7</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="center" rowspan="1" colspan="1">63.6</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">33.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">75</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">50</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">100</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total</td><td valign="top" align="center" rowspan="1" colspan="1">58</td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">72</td><td valign="top" align="center" rowspan="1" colspan="1">80.6</td><td valign="top" align="center" rowspan="1" colspan="1">26</td><td valign="top" align="center" rowspan="1" colspan="1">10</td><td valign="top" align="center" rowspan="1" colspan="1">36</td><td valign="top" align="center" rowspan="1" colspan="1">72.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;12</td><td valign="top" align="center" rowspan="1" colspan="1">36</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">17</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;12</td><td valign="top" align="center" rowspan="1" colspan="1">22</td><td valign="top" align="center" rowspan="1" colspan="1">12</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">9</td><td valign="top" align="center" rowspan="1" colspan="1">10</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>p</italic>
<xref rid="table-fn19" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.0021</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.0004</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="table-fn19a"><p>Bold values represented <italic>p</italic> &#x0003c; 0.05.</p></fn><fn id="table-fn19"><label>
<sup>a</sup>
</label><p>Fisher&#x02019;s exact test of prognosis difference between children aged &#x0003c;12&#x02005;years and those aged &#x02265;12&#x02005;years.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="s4"><label>4</label><title>Discussion</title><p>In another study, ALL was reported as the most common type of pediatric acute leukemia, accounting for approximately 75%&#x02013;80% of cases (<xref rid="B11" ref-type="bibr">11</xref>). In our study, 66.7% of pediatric leukemia patients were diagnosed with ALL. This discrepancy might be due to differences in the inclusion and exclusion criteria, as well as variations related to environmental factors and racial demographics.</p><p>The most common acute infection observed among the enrolled acute leukemia patients in our study were upper respiratory tract infection (46.3%), followed by pneumonia (34.3%), sepsis (8.3%), and oral infections (7.4%). Neutropenia emerged as the leading risk factor for infection development (<xref rid="B12" ref-type="bibr">12</xref>). In addition, several other factors contribute to increased infection risk, including compromised cellular or humoral immunity, disruption of natural barriers (such as skin and mucous membranes), and the use of medical devices, such as vascular access catheters (<xref rid="B13" ref-type="bibr">13</xref>). Often, patients are affected by a combination of these risk factors, which can further elevate their susceptibility to infections and the risk of adverse outcomes.</p><p>We found that pneumonia (47.2% vs. 27.8%, <italic>p</italic>&#x02009;=&#x02009;0.045) and sepsis (19.4% vs. 2.8%, <italic>p</italic>&#x02009;=&#x02009;0.006) were significantly more common in AML than in ALL cases. This can be explained by the differing immunological deficits associated with each leukemia type. In AML, deficits in neutrophilic granulocytes lead to a higher incidence of bacterial and fungal infections, whereas in ALL, deficits in lymphocytes result in hypogammaglobulinemia, leading to reduced cell-mediated immunity (<xref rid="B14" ref-type="bibr">14</xref>).</p><p>During treatment for ALL and AML, different agents and schedules might be employed, leading to differences in prognosis (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). Both the disease and its therapies place a heavy burden on the developing immune system. In acute leukemia, normal production of blood cells in the bone marrow is disrupted (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>) and leukemia cells crowd out healthy white blood cells, including lymphocytes and granulocytes, which are both essential for immune defense. This results in children experiencing frequent infections and fevers, as the body struggles to mount an effective response against pathogens.</p><p>Treatment for acute leukemia, primarily via chemotherapy, further exacerbates immune dysfunction (<xref rid="B18" ref-type="bibr">18</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>). Chemotherapy targets rapidly dividing cells, affecting not only cancer cells but also healthy immune cells, leading to suppression of the immune system. This increases children&#x02019;s susceptibility to infections both during and after treatment. The effects of chemotherapy on the immune system can persist even after treatment completion, as evidenced by persistent abnormalities in immune parameters such as lymphocyte subsets and natural killer cell function. In the context of AML, children often experience multiple episodes of infection during intensive treatment, with sepsis being the most common (<xref rid="B15" ref-type="bibr">15</xref>). Infection-related mortality rates are in the range of 5.4%&#x02013;7.3%. In ALL, the induction and consolidation phases pose significant risks for infections due to severe neutropenia. Infection-related mortality in ALL is generally lower, in the range of 2%&#x02013;4%; however, infections remain a primary cause of treatment-related mortality. Understanding these risks is crucial for developing effective strategies to manage and prevent infections during leukemia treatment.</p><p>It is also interesting to note that a previous study in children and adolescents with ALL showed there were no significant associations between sex, race, age, and the development of acute respiratory infections (<xref rid="B22" ref-type="bibr">22</xref>). Another study investigating childhood AML with infections showed that age above 16&#x02005;years was a factor associated with infection-related mortality (<xref rid="B23" ref-type="bibr">23</xref>). In general, independent of acute infections, the survival rate of ALL is highest when children diagnosed at 1&#x02013;4&#x02005;years of age, with a decline observed in older age groups. Infants aged under 1&#x02005;year have the lowest survival rate in both ALL and AML (<xref rid="B24" ref-type="bibr">24</xref>). In our study, children aged under 12&#x02005;years demonstrated a more favorable prognosis in both ALL and AML populations. The underlying pathophysiological mechanisms need further investigation and might be related to deficiencies of key factors in metabolism (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>).</p><p>The present study has some limitations. Notably, the sample sizes in certain subgroups&#x02014;particularly when comparing infection type and age&#x02014;were relatively small. Therefore, the conclusions drawn need to be validated in more robust studies, such as meta-analyses or large-scale studies.</p></sec><sec sec-type="conclusions" id="s5"><label>5</label><title>Conclusion</title><p>In this study, by analyzing clinical data collected over an 18-year period at our hospital, we found a significantly higher incidence of pneumonia and sepsis in children diagnosed with AML compared to those with ALL. Younger children with AML or ALL who developed acute infections tended to have a better prognosis than older children.</p></sec></body><back><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="s7"><title>Ethics statement</title><p>The studies involving humans were approved by Ethical Committee of the Second Affiliated Hospital of Harbin Medical University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>SsL: Conceptualization, Formal analysis, Supervision, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. SnL: Conceptualization, Formal analysis, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. YC: Data curation, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. SJ: Data curation, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. KL: Data curation, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. FC: Data curation, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing, Supervision.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s11"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s12"><title>Publisher's note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadian0-Hafshejani</surname><given-names>A</given-names></name><name><surname>Farber</surname><given-names>IM</given-names></name><name><surname>Kheiri</surname><given-names>S</given-names></name></person-group>. <article-title>Global incidence and mortality of childhood leukemia and its relationship with the human development Index</article-title>. <source>PLoS One</source>. (<year>2024</year>) <volume>19</volume>(<issue>7</issue>):<fpage>e0304354</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0304354</pub-id><pub-id pub-id-type="pmid">38954710</pub-id>
</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunger</surname><given-names>SP</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Devidas</surname><given-names>M</given-names></name><name><surname>Camitta</surname><given-names>BM</given-names></name><name><surname>Gaynon</surname><given-names>PS</given-names></name><name><surname>Winick</surname><given-names>NJ</given-names></name><etal/></person-group>
<article-title>Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children&#x02019;s oncology group</article-title>. <source>J Clin Oncol</source>. (<year>2012</year>) <volume>30</volume>(<issue>14</issue>):<fpage>1663</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2011.37.8018</pub-id><pub-id pub-id-type="pmid">22412151</pub-id>
</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creutzig</surname><given-names>U</given-names></name><name><surname>Zimmermann</surname><given-names>M</given-names></name><name><surname>Lehrnbecher</surname><given-names>T</given-names></name><name><surname>Graf</surname><given-names>N</given-names></name><name><surname>Hermann</surname><given-names>J</given-names></name><name><surname>Niemeyer</surname><given-names>CM</given-names></name><etal/></person-group>
<article-title>Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98</article-title>. <source>J Clin Oncol</source>. (<year>2006</year>) <volume>24</volume>(<issue>27</issue>):<fpage>4499</fpage>&#x02013;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2006.06.5037</pub-id><pub-id pub-id-type="pmid">16983120</pub-id>
</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>A</given-names></name><name><surname>Elballushi</surname><given-names>R</given-names></name><name><surname>Joshi</surname><given-names>R</given-names></name><name><surname>Anjanappa</surname><given-names>S</given-names></name><name><surname>Akter</surname><given-names>M</given-names></name><name><surname>Arif</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Assessment of the prevalence of infections in pediatric patients with acute lymphoblastic leukemia</article-title>. <source>Cureus</source>. (<year>2023</year>) <volume>15</volume>(<issue>10</issue>):<fpage>e46837</fpage>. <pub-id pub-id-type="doi">10.7759/cureus.46837</pub-id><pub-id pub-id-type="pmid">37954717</pub-id>
</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>PA</given-names></name><name><surname>DeGroote</surname><given-names>NP</given-names></name><name><surname>Jackson</surname><given-names>K</given-names></name><name><surname>Cash</surname><given-names>T</given-names></name><name><surname>Castellino</surname><given-names>SM</given-names></name><name><surname>Jaggi</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Infectious events in pediatric patients with acute lymphoblastic leukemia/lymphoma undergoing evaluation for fever without severe neutropenia</article-title>. <source>Cancer</source>. (<year>2022</year>) <volume>128</volume>(<issue>23</issue>):<fpage>4129</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.34476</pub-id><pub-id pub-id-type="pmid">36238979</pub-id>
</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="book"><collab>PDQ Pediatric Treatment Editorial Board</collab>. <source>Childhood Acute Lymphoblastic Leukemia Treatment (PDQ&#x000ae;): Health Professional Version. 2024 Dec 5. in: PDQ Cancer Information Summaries</source>. <publisher-loc>Bethesda, MD</publisher-loc>: <publisher-name>National Cancer Institute (US)</publisher-name> (<year>2002</year>).</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>C</given-names></name><name><surname>Hall</surname><given-names>G</given-names></name><name><surname>Clarke</surname><given-names>RT</given-names></name></person-group>. <article-title>Acute leukaemia in children: diagnosis and management</article-title>. <source>Br Med J</source>. (<year>2009</year>) <volume>338</volume>:<fpage>b2285</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.b2285</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venge</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name></person-group>. <article-title>Diagnosis and monitoring of acute infections with emphasis on the novel biomarker human neutrophil lipocalin</article-title>. <source>J Appl Lab Med</source>. (<year>2019</year>) <volume>3</volume>(<issue>4</issue>):<fpage>664</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1373/jalm.2018.026369</pub-id><pub-id pub-id-type="pmid">31639734</pub-id>
</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Caliendo</surname><given-names>AM</given-names></name><name><surname>Hanson</surname><given-names>KE</given-names></name></person-group>. <article-title>COVID-19: diagnosis</article-title>. In: <person-group person-group-type="editor"><name><surname>RF</surname><given-names>C</given-names></name></person-group>, editor. <source>UpToDate</source>. <publisher-name>Wolters Kluwer</publisher-name>. (<year>2024</year>). Available at: <ext-link xlink:href="https://www.uptodate.com/contents/covid-19-diagnosis" ext-link-type="uri">https://www.uptodate.com/contents/covid-19-diagnosis</ext-link> (<comment>accessed on March 23, 2025</comment>).</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="other"><collab>CDC</collab>. <article-title>Overview of Testing for SARS-CoV-2</article-title>. <comment>Available online at:</comment>
<ext-link xlink:href="https://www.cdc.gov/covid/hcp/clinical-care/overview-testing-sars-cov-2.html" ext-link-type="uri">https://www.cdc.gov/covid/hcp/clinical-care/overview-testing-sars-cov-2.html</ext-link> (<comment>accessed on March 23, 2025</comment>).</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tebbi</surname><given-names>CK</given-names></name></person-group>. <article-title>Etiology of acute leukemia: a review</article-title>. <source>Cancers (Basel)</source>. (<year>2021</year>) <volume>13</volume>(<issue>9</issue>):<fpage>2256</fpage>. <pub-id pub-id-type="doi">10.3390/cancers13092256</pub-id><pub-id pub-id-type="pmid">34066700</pub-id>
</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rolston</surname><given-names>KVI</given-names></name></person-group>. <article-title>Infections in patients with acute leukemia</article-title>. In: Maschmeyer G, Rolston K, editors. <italic>Infections in Hematology</italic>. <publisher-loc>Berlin and Heidelberg</publisher-loc>: <publisher-name>Springer</publisher-name> (<year>2014</year>). p. <fpage>3</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-662-44000-1_1</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dropulic</surname><given-names>LK</given-names></name><name><surname>Lederman</surname><given-names>HM</given-names></name></person-group>. <article-title>Overview of infections in the immunocompromised host</article-title>. <source>Microbiol Spectr</source>. (<year>2016</year>) <volume>4</volume>(<issue>4</issue>):<comment>DMIH2-0026-2016</comment>. <pub-id pub-id-type="doi">10.1128/microbiolspec.DMIH2-0026-2016</pub-id><pub-id pub-id-type="pmid">27726779</pub-id>
</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logan</surname><given-names>C</given-names></name><name><surname>Koura</surname><given-names>D</given-names></name><name><surname>Taplitz</surname><given-names>R</given-names></name></person-group>. <article-title>Updates in infection risk and management in acute leukemia</article-title>. <source>Hematology Am Soc Hematol Educ Program</source>. (<year>2020</year>) <volume>2020</volume>(<issue>1</issue>):<fpage>135</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1182/hematology.2020000098</pub-id><pub-id pub-id-type="pmid">33275701</pub-id>
</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlesse</surname><given-names>F</given-names></name><name><surname>de Sousa</surname><given-names>AVL</given-names></name></person-group>. <article-title>Infections in children and adolescents with acute leukemia</article-title>. <source>EJC Paediatric Oncology</source>. (<year>2024</year>) <volume>3</volume>:<fpage>100142</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejcped.2024.100142</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sison</surname><given-names>EA</given-names></name><name><surname>Brown</surname><given-names>P</given-names></name></person-group>. <article-title>The bone marrow microenvironment and leukemia: biology and therapeutic targeting</article-title>. <source>Expert Rev Hematol</source>. (<year>2011</year>) <volume>4</volume>(<issue>3</issue>):<fpage>271</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1586/ehm.11.30</pub-id><pub-id pub-id-type="pmid">21668393</pub-id>
</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group>. <article-title>Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development</article-title>. <source>Exp Hematol Oncol</source>. (<year>2021</year>) <volume>10</volume>(<issue>1</issue>):<fpage>39</fpage>. <pub-id pub-id-type="doi">10.1186/s40164-021-00233-2</pub-id><pub-id pub-id-type="pmid">34246314</pub-id>
</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witkowski</surname><given-names>MT</given-names></name><name><surname>Lasry</surname><given-names>A</given-names></name><name><surname>Carroll</surname><given-names>WL</given-names></name><name><surname>Aifantis</surname><given-names>I</given-names></name></person-group>. <article-title>Immune-based therapies in acute leukemia</article-title>. <source>Trends Cancer</source>. (<year>2019</year>) <volume>5</volume>(<issue>10</issue>):<fpage>604</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.trecan.2019.07.009</pub-id><pub-id pub-id-type="pmid">31706508</pub-id>
</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaldoyanidi</surname><given-names>S</given-names></name><name><surname>Nagorsen</surname><given-names>D</given-names></name><name><surname>Stein</surname><given-names>A</given-names></name><name><surname>Ossenkoppele</surname><given-names>G</given-names></name><name><surname>Subklewe</surname><given-names>M</given-names></name></person-group>. <article-title>Immune biology of acute myeloid leukemia: implications for immunotherapy</article-title>. <source>J Clin Oncol</source>. (<year>2021</year>) <volume>39</volume>(<issue>5</issue>):<fpage>419</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.20.00475</pub-id><pub-id pub-id-type="pmid">33434043</pub-id>
</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serroukh</surname><given-names>Y</given-names></name><name><surname>H&#x000e9;bert</surname><given-names>J</given-names></name><name><surname>Busque</surname><given-names>L</given-names></name><name><surname>Mercier</surname><given-names>F</given-names></name><name><surname>Rudd</surname><given-names>CE</given-names></name><name><surname>Assouline</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment</article-title>. <source>Blood Rev</source>. (<year>2023</year>) <volume>57</volume>:<fpage>100991</fpage>. <pub-id pub-id-type="doi">10.1016/j.blre.2022.100991</pub-id><pub-id pub-id-type="pmid">35941029</pub-id>
</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senapati</surname><given-names>J</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Habib</surname><given-names>D</given-names></name><name><surname>Haddad</surname><given-names>FG</given-names></name><name><surname>Jain</surname><given-names>N</given-names></name><name><surname>Short</surname><given-names>NJ</given-names></name><etal/></person-group>
<article-title>Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy</article-title>. <source>Leuk Lymphoma</source>. (<year>2025</year>):<fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1080/10428194.2025.2449582</pub-id><pub-id pub-id-type="pmid">39791458</pub-id>
</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hakim</surname><given-names>H</given-names></name><name><surname>Dallas</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Pei</surname><given-names>D</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Flynn</surname><given-names>PM</given-names></name><etal/></person-group>
<article-title>Acute respiratory infections in children and adolescents with acute lymphoblastic leukemia</article-title>. <source>Cancer</source>. (<year>2016</year>) <volume>122</volume>(<issue>5</issue>):<fpage>798</fpage>&#x02013;<lpage>805</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.29833</pub-id><pub-id pub-id-type="pmid">26700662</pub-id>
</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>L</given-names></name><name><surname>Lange</surname><given-names>BJ</given-names></name><name><surname>Gerbing</surname><given-names>RB</given-names></name><name><surname>Alonzo</surname><given-names>TA</given-names></name><name><surname>Feusner</surname><given-names>J</given-names></name></person-group>. <article-title>Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia</article-title>. <source>Blood</source>. (<year>2007</year>) <volume>110</volume>(<issue>10</issue>):<fpage>3532</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2007-05-091942</pub-id><pub-id pub-id-type="pmid">17660380</pub-id>
</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Rong</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Kang</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Impact of age on the survival of pediatric leukemia: an analysis of 15083 children in the SEER database</article-title>. <source>Oncotarget</source>. (<year>2016</year>) <volume>7</volume>(<issue>50</issue>):<fpage>83767</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.11765</pub-id><pub-id pub-id-type="pmid">27590519</pub-id>
</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Werner</surname><given-names>ER</given-names></name><name><surname>Werner-Felmayer</surname><given-names>G</given-names></name><name><surname>Wachter</surname><given-names>H</given-names></name></person-group>. <article-title>Tetrahydrobiopterin and cytokines</article-title>. <source>Proc Soc Exp Biol Med</source>. (<year>1993</year>) <volume>203</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.3181/00379727-203-43566a</pub-id><pub-id pub-id-type="pmid">8475129</pub-id>
</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traeger</surname><given-names>RS</given-names></name><name><surname>Woodcock</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Vasquez-Vivar</surname><given-names>J</given-names></name></person-group>. <article-title>Tetrahydrobiopterin as a rheostat of cell resistance to oxidant injury</article-title>. <source>Redox Biol</source>. (<year>2025</year>) <volume>79</volume>:<fpage>103447</fpage>. <pub-id pub-id-type="doi">10.1016/j.redox.2024.103447</pub-id><pub-id pub-id-type="pmid">39642597</pub-id>
</mixed-citation></ref></ref-list></back></article>